14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SYK vs EW: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SYK Overall Winner
6-Pillar Tally: SYK 3 – 3 EW
Matrix Metrics: SYK 5 – 5 EW
As of Nov 16, 2026, Stryker Corporation (SYK) is the stronger overall head-to-head candidate over Edwards Lifesciences Corp (EW) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Options & Positioning, R&D & Supply-Chain Moat). SYK carries a Unified Composite Score of 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin), whereas EW carries 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin).
Competes within the Medical Devices value chain with $118.9B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment41.7% of Rev ($11.0B)
90D Engineering Disclosures0 Published · Surgical Robotics
EW Moat ProfileScale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $60.8B market capitalization and 28.8% operating margin.
OpEx & R&D Reinvestment49.2% of Rev ($3.28B)
90D Engineering Disclosures0 Published
Investor FAQ SYK vs EW Key Questions & Quantitative Answers
As of Nov 16, 2026, Stryker Corporation (SYK) is the stronger overall head-to-head candidate over Edwards Lifesciences Corp (EW) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Options & Positioning, R&D & Supply-Chain Moat). SYK carries a Unified Composite Score of 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin), whereas EW carries 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin). Technically, SYK sits in a Neutral phase (RSI 51.5, SURGE options structure) and EW sits in a Markup phase (RSI 79.4, UNCLASSIFIED options structure).
EW leads the Growth & Scale pillar: SYK posts +7.6% YoY revenue growth and -11.7% YoY earnings growth on $26.3B TTM revenue (65.7% gross margin, 24.0% operating margin), compared with EW at +10.5% YoY revenue growth and +6.7% YoY earnings growth on $6.67B TTM revenue (78.0% gross margin, 28.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SYK cumulative revenue shifted +84.7% while EW shifted +63.2%. In operating R&D and SG&A reinvestment, SYK deploys 41.7% of Rev ($11.0B) (0 90-day corporate R&D disclosures) versus 49.2% of Rev ($3.28B) (0 disclosures) for EW.
SYK screens cheaper on headline valuation multiples. SYK trades at 19.0x Forward P/E, 33.3x Trailing P/E, 1.54x PEG, and 5.0x EV/Revenue (17.4% FCF margin), whereas EW trades at 31.6x Forward P/E, 61.5x Trailing P/E, 2.33x PEG, and 8.8x EV/Revenue (21.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYK (16.0% ROE) versus EW (9.3% ROE) capital efficiency.
In options market volatility and institutional positioning, SYK carries 28.1% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.30x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.22β · 50% Vol realized risk). By comparison, EW carries 24.6% implied volatility (34th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.44β · 24% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.